First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial. This is an ASCO ...
This demanding study from Huneman (Why?), director of research at the Institute of History and Philosophy of Science and Technology in Paris, examines how predictive algorithms influence identity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results